Essential Drug List To Be Released In Two Phases
This article was originally published in PharmAsia News
Executive Summary
According to authoritative sources, China will adopt a two-step approach for its national essential drug list release: a mini-list comprising 178 western medicines and 78 patent TCMs will be issued soon, while an enriched list is expected to come out after Aug. 16. China's Ministry of Health, National Development and Reform Commission and Ministry of Human Resources and Social Security have jointly discussed and confirmed the first batch of documents for healthcare reform, including the essential drug list, essential drug pricing, as well as tender and purchase specifics. Relevant administrations have selected Class I medical care institutions to pilot the mini-list. Another list may leave 5 percent of total medicines to local governments for selection and adjustment; however, the issue of dealing with specific drugs is still outstanding. (Click here for more - Chinese Language)
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.